m3taversal
a756745c18
- What: Converted 132 broken wiki links to plain text across 41 health domain files. Added Vida to the Active Agents table in CLAUDE.md. - Why: Leo's PR #15 review required these two changes before merge. - Details: Broken links were references to claims that don't yet exist (demand signals). Brackets removed so they read as plain text rather than broken links. Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
28 lines
3.1 KiB
Markdown
28 lines
3.1 KiB
Markdown
---
|
|
description: Moderna/Merck intismeran encodes up to 34 patient-specific neoantigens and 5-year data shows sustained melanoma recurrence reduction with Phase 3 trials across NSCLC bladder and renal cancer and potential FDA approval by 2028
|
|
type: claim
|
|
domain: health
|
|
created: 2026-02-17
|
|
source: "Merck 5-year intismeran data announcement 2025; Scientific American personalized mRNA vaccines 2025; Fierce Biotech melanoma risk reduction data; Moderna pipeline disclosures 2026"
|
|
confidence: likely
|
|
---
|
|
|
|
# personalized mRNA cancer vaccines show sustained 49 percent reduction in melanoma recurrence after five years representing a genuinely novel therapeutic paradigm
|
|
|
|
The Moderna/Merck partnership on intismeran (mRNA-4157/V940) represents the most advanced non-COVID mRNA therapeutic and a genuinely novel approach to cancer treatment. The vaccine is manufactured individually for each patient: tumor DNA is sequenced, up to 34 neoantigens are selected, and personalized mRNA is produced to train the patient's immune system against their specific tumor mutations.
|
|
|
|
Five-year data showed sustained 49% reduction in melanoma recurrence risk when combined with Keytruda (pembrolizumab) versus Keytruda alone. The Phase 3 melanoma trial is fully enrolled with interim results expected in 2026. Phase 3 trials have been initiated in two NSCLC (lung cancer) settings, and 8 Phase 2/3 trials are underway across melanoma, NSCLC, bladder cancer, and renal cell carcinoma. Potential FDA approval could come as early as 2028.
|
|
|
|
The mRNA platform extends beyond cancer vaccines. Rare disease protein replacement (mRNA-3927 for propionic acidemia, mRNA-3705 for methylmalonic acidemia) uses mRNA to instruct cells to produce missing proteins -- a fundamentally new approach that doesn't permanently alter the genome but requires repeated dosing. Emerging RNA modalities including self-amplifying RNA, circular RNA, and siRNA expand the therapeutic toolkit further.
|
|
|
|
The 10-year trajectory: 5-10 approved mRNA products beyond COVID vaccines by 2035. Personalized cancer vaccines become standard adjuvant treatment for high-risk solid tumors. Combination respiratory vaccines (flu+COVID+RSV) simplify annual immunization. The wild card is autoimmune disease -- mRNA-based immune tolerance therapies could open an entirely new therapeutic category.
|
|
|
|
---
|
|
|
|
Relevant Notes:
|
|
- [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] -- personalized manufacturing for each patient is inherently expensive even at scale, creating a new $5-10B annual cost center by 2035
|
|
- [[gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment]] -- mRNA and gene editing share LNP delivery infrastructure, forming a horizontal platform
|
|
- [[AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics]] -- AI-accelerated neoantigen selection is critical to scaling personalized vaccine manufacturing
|
|
|
|
Topics:
|
|
- health and wellness
|